you are here:

Dishman Carbogen Amcis Ltd.

BSE: 540701 | NSE: DCAL |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE385W01011 | SECTOR: Miscellaneous

BSE Live

Nov 25, 16:00
144.05 -0.85 (-0.59%)
Volume
AVERAGE VOLUME
5-Day
63,432
10-Day
55,508
30-Day
39,406
46,477
  • Prev. Close

    144.90

  • Open Price

    149.75

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    0.00 (0)

NSE Live

Nov 25, 15:58
144.00 -0.85 (-0.59%)
Volume
AVERAGE VOLUME
5-Day
594,326
10-Day
512,998
30-Day
349,117
248,171
  • Prev. Close

    144.85

  • Open Price

    143.80

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    144.00 (124)

Annual Report

For Year :
2018 2017

Chairman's Speech

Dear Shareholders,

It is my honour and privilege to interact with you as the Chairman of the Board. The fiscal has been an exciting one for the Company. We took the opportunity to strengthen our business by reducing our operating expenses and capital investment, while continuing to drive our efforts towards utilising our capacities in an optimal manner. We remain on course to meet our strategic targets and deliver sustainably. We are fully confident that Dishman will continue to succeed and thrive in the future.

Today, we are a global and integrated CRAMS player with strong capabilities across the value chain - from process research and development to late-stage clinical and commercial manufacturing. We are proud to have become the preferred outsourcing partner across continents and countries and also to service customers from all the key advanced markets including US, Europe and Asia. The global pharmaceutical and bio-pharmaceutical CRAMS market has been growing year on year, with an increasing emphasis on generic alternatives from developed countries. Global pharmaceutical companies are focusing on marketing and discovery, and are outsourcing drug development, clinical trials and manufacturing.

We are leveraging our key capabilities of strong chemistry skills, low cost and flexible manufacturing processes, focused operations and our product portfolio. These factors have helped Dishman establish strong customer relationships, leading to scale-up in our CRAMS and API businesses, and have helped sustain higher profitability and better return ratios. These are also the factors that we capitalise on to differentiate ourselves from other Indian CRAMS players.

Laying our Foundation for Long-Term Growth

At Dishman, our focus continues to be on improving our margins with higher capacity utilisation and high margin revenues from the niche and highly potent compounds. We are also focusing on improving our asset turnover and return ratios, and improving our liquidity to capture business opportunities for even stronger growth. We have been gaining the flexibility to manufacture from either of the facilities, thereby reducing dependence on a single plant. This will also free up the capacity constraint at Carbogen Amcis, allowing the site to focus on early phase chemical synthesis work. Going forward, we remain on course to meet our strategic targets and deliver sustainably. We are confident of the Dishman Group continuing to succeed and thrive in the future.

I take this opportunity to convey thanks to our Board Members for their constant guidance and support. We look forward to their support as we continue to create long-term value for our stakeholders.

On behalf of the Board, we thank our the shareholders for believing in us, the Management of Dishman Carbogen Amcis, and the employees for their loyalty and contribution.

Janmejay R. Vyas

Chairman & Managing Director